CS
ACOR

Candriam SCA’s Acorda Therapeutics ACOR Stock Holding History

Candriam SCA’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-592
Closed -$1.4M – 753
2017
Q2 		$1.4M Hold
592
– – 0.03% 527
2017
Q1 		$1.49M Buy
592
+92
+18% +$265K 0.03% 494
2016
Q4 		$1.13M Hold
500
– – 0.03% 496
2016
Q3 		$1.25M Hold
500
– – 0.03% 451
2016
Q2 		$1.53M Hold
500
– – 0.04% 354
2016
Q1 		$1.58M Sell
500
-183
-27% -$760K 0.04% 359
2015
Q4 		$3.51M Buy
683
+42
+7% +$184K 0.09% 230
2015
Q3 		$2.04M Buy
641
+41
+7% +$159K 0.05% 338
2015
Q2 		$2.4M Buy
+600
New +$2.32M 0.05% 334
2015
Q1 		– Sell
-1,000
Closed -$4.9M – 667
2014
Q4 		$4.9M Buy
+1,000
New +$4.29M 0.1% 235

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Candriam SCA's ACOR Position: Q3 2017 in Review

Candriam SCA sold out of Acorda Therapeutics (ACOR) in Q3 2017, closing a stake of 592 shares — an estimated $1.4M sold.

Candriam SCA first reported a position in ACOR in Q4 2014 and held it in 10 quarters. The position peaked at $4.9M in Q4 2014. 152 funds tracked by Wall St. Rank hold ACOR as of Q3 2017.

  • Candriam SCA reported no remaining Acorda Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Candriam SCA sold 592 Acorda Therapeutics shares in Q3 2017, an estimated $1.4M.
  • Candriam SCA first reported a position in Acorda Therapeutics in Q4 2014 and held it in 10 quarters.
  • Candriam SCA's Acorda Therapeutics position peaked at $4.9M in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2017.

Based on Candriam SCA's 13F filing for Q3 2017, filed 3 Nov 2017.